Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news articles that may have effected Accern Sentiment’s analysis:

A number of research analysts recently weighed in on VNDA shares. Oppenheimer Holdings, Inc. started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price target on the stock. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Piper Jaffray Companies reissued an “overweight” rating and set a $23.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, May 25th. Finally, HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $21.33.

Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 3.43% during mid-day trading on Tuesday, hitting $15.50. 440,220 shares of the stock traded hands. The stock’s market cap is $693.13 million. Vanda Pharmaceuticals has a 1-year low of $11.58 and a 1-year high of $18.00. The company’s 50 day moving average price is $16.07 and its 200-day moving average price is $14.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.88%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.01 EPS. Analysts predict that Vanda Pharmaceuticals will post ($0.61) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals (VNDA) Given Daily Coverage Optimism Score of 0.16” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.